photo of immunotherapy vialThe immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.

I would really love you to Leave a Reply and let me know what other content you would like from me. Thank You!

This site uses Akismet to reduce spam. Learn how your comment data is processed.